Arcellx Inc 's ROA from the fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Arcellx Inc 's ROA in the fourth quarter of 2025?
Arcellx Inc recorded a cumulative net loss of $-229 million during 12 months ending in the fourth quarter of 2025, resulting in a negative return on assets (ROA) of -36.24%.

However, within the Healthcare sector 545 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2025 from 3817 to 4382.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter
Y / Y Total Assets Change	-12.35 %	-11.67 %	-12.91 %	-14.4 %	-13.82 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-229	-218	-188	-162	-107
Return On Assets (TTM)	-36.24 %	-33.37 %	-27.86 %	-23.28 %	-14.81 %
ACLX's Total Ranking	# 4382	# 3817	# 3735	# 3688	# 4017
Total Assets (TTM) in million	604	656	619	648	689
Seq. Total Assets Change	-7.92 %	5.95 %	-4.47 %	-5.96 %	-7.2 %
Seq. Net Income Change	-	-	-	-	-

ACLX's 5 Years Annual ROA >> Back to ACLX Management Effectiveness >> Compare ACLX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 70
Sector	# 546
Overall	# 4344

Return On Assets Statistics
High	Average	Low
-5.21 %	-25.52 %	-59.3 %
(Sep 30 2024)		(Dec 31 2022)

News about Arcellx Inc Return on Assets ROA

Pioneering Advances in CAR T-Cell Therapy for Multiple Myeloma Arcellx and Kites Breakthrough Developments

In a rapidly evolving landscape of cancer therapeutics, cell therapies are heralding a new era of hope for patients battling difficult-to-treat malignancies. Among the promising developments in this domain is Arcellx s innovative approach to multiple myeloma (MM), a blood cancer notorious for its relapsing nature. This article delves into the significant strides made by Arcellx, particularly through its lead immunotherapy candidate, anitocabtagene autoleucel (anitocel), in collaboration with Kite, a Gilead Company. Our focus will encompass the recent clinical presentations at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, ongoing Phase 3 studies, and the overall impact of these initiatives on the field of oncology. An Overview of Multiple Myeloma and the Need for Innovative Therapies Multiple myeloma is characterized by the uncontrolled proliferation of abnormal plasma cells in the bone marrow. The disease often becomes more difficult to treat after initial therapies, resulting in what is termed relapsed or refractory multiple myeloma (RRMM). Current treatment modalities include chemotherapy, corticosteroids, and immunotherapy; however, many patients ultimately succumb to the disease due to inadequate responses or relapse. This scenario underscores the urgent need for novel therapeutic options that can improve outcomes and prolong survival for patients with RRMM.

Financial Statements
Arcellx Inc 's Assets	$ 604 million	ACLX's Balance sheet
Arcellx Inc 's Income	$ -58 million	Quarterly ACLX's Income Statement
ACLX's Income by Division		See ACLX's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	FY
Y / Y Total Assets Change	-2.24 %	-13.82 %	178.94 %	-	-
Total Assets in million	674	689	800	287	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-229	-107	-71	-189	0
Annual Return On Assets	-33.98 %	-15.58 %	-8.84 %	-65.82 %	-

ACLX's 5 Years Annual ROA >> Back to ACLX Management Effectiveness >> Compare ACLX ROA to its Competitors

More Return On Assets Ratios
ACLX's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ACLX's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ACLX's Competitors
Subscribers only: Roa for Arcellx Inc 's Suppliers
Subscribers only: Return On Assets for ACLX's Customers

You may also want to know
ACLX's Roi	ACLX's Inventory Turnover Ratio	ACLX's Growth Rates	ACLX's Dividend Comparisons
	ACLX's Profitability Ratios	ACLX's Asset Turnover Ratio	ACLX's Dividend Growth
ACLX's Roe	ACLX's Valuation Ratios	ACLX's Financial Strength Ratios	ACLX's Dividend Payout Ratio

Companies with similar Return On Assets at Dec 31 2025, within Healthcare Sector

ROA

Date modified: 2026-09-18T13:11:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.